TL;DR — Japan’s regenerative medicine treatment plans operate under a notification-and-filing system. Regulatory acceptance is not approval of any individual therapy, and each plan is tied to specific conditions. Describing “filed with the MHLW” as “government certified” is the exact misleading pattern regulators have named in their own guidance. Taiwan’s rules are stricter: advertising requires pre-publication review starting in 2026. Cross-border ads in foreign languages fall between the two systems.

A Traditional Chinese ad appeared in my social feed. It promoted stem cell therapy from a Japanese clinic, centered on autologous adipose-derived mesenchymal stem cells. The ad included information about one-on-one consultation sessions in Taipei, along with a photograph of what appeared to be a government filing document.

I had been evaluating the feasibility of bringing a cell therapy to market in Taiwan at the time, so I was reading this kind of material more carefully than most people would. When I saw that document photo, my first thought was: what does that piece of paper actually represent? Whether the therapy works was, for the moment, a secondary question.

After an afternoon checking the ad’s claims against the MHLW’s public database, I decided to write this up. This piece is not about that particular ad — no specific provider is named or implicated here.

What is worth writing about is the structural problem the ad exposed: the legal status of a document, and the status an advertisement implies it has, can be very different things. That gap is the key to understanding how misleading advertising in out-of-pocket regenerative medicine tends to work.

The Japanese law governing cell-based regenerative medicine is the Act on the Safety of Regenerative Medicine (再生医療等の安全性の確保等に関する法律), commonly rendered in English as the Regenerative Medicine Safety Act.

Under Article 4, a medical institution wishing to provide cell-based regenerative therapy must first submit a “regenerative medicine treatment plan” (再生医療等提供計画). The plan must specify the technology name, the risk classification (Type 1, Type 2, or Type 3), and the name of the target condition the institution intends to treat.

The plan is submitted to the Minister of Health, Labour and Welfare — in practice, accepted by the regional Bureau of Health and Welfare — after review by a certified committee.

The critical word here is 届出. In Japanese administrative law, 届出 means notification or filing for the record. It does not carry the force of 承認 (recognition) or 許可 (permission/approval).

Regulators have been explicit about this distinction. Both the MHLW and the Japanese Society for Regenerative Medicine have flagged it: 届出 is a notification system, not a recognition system. If advertising language leads readers to believe the government has evaluated and endorsed the therapy’s efficacy, that constitutes misleading advertising.

The 2026 edition of the MHLW’s guidance document on medical advertising — 医療広告規制におけるウェブサイト等の事例解説書 — added a dedicated chapter on out-of-pocket regenerative medicine, naming the problem directly:

「自由診療で行われる再生医療や、幹細胞培養上清液及びエクソソーム等を用いる医療に関する誇大広告・虚偽広告、再生医療を実施する医療機関を厚生労働省が個別に承認等しているかのように誤認させる広告が散見される」

In plain terms: misleading and false advertising is commonly seen in out-of-pocket regenerative medicine — including the use of stem cell conditioned medium and exosomes — and this includes advertising that causes readers to believe the MHLW has individually approved the medical institution delivering the therapy.

When regulators put a specific pattern into their guidance documents, it usually means they’ve seen it often enough to warrant naming it.

Each Plan Is Tied to One Set of Conditions

The second detail that tends to get overlooked is this: a treatment plan must specify not only the technology, but also the target conditions.

This means that if the same cell technology is to be applied to a different condition, a separate filing is required in principle — and a separate committee review. A plan filed for “chronic pain” covers chronic pain.

So there is one concrete check worth running on any ad of this type: compare the conditions the ad claims to treat against the target conditions listed in the institution’s accepted plan.

Japan’s database is publicly accessible. The MHLW’s list of accepted treatment plans — 届出された再生医療等提供計画 — is divided into three pages by risk classification: Type 1 covers high-risk technologies such as iPS cells and gene therapies; Type 2 covers medium-risk technologies such as mesenchymal stem cells; Type 3 covers lower-risk technologies such as NK cells. Each entry links to a document that states the indicated conditions and enrollment criteria in plain language.

I looked up the clinic from that ad and found six registered plans. The accepted indications covered three broad categories. The number of conditions named across the ad’s main copy and extended landing pages came to over forty.

The size of that gap requires no commentary from me. Put the two lists side by side and you can see it for yourself.

Taiwan’s Standard Is Stricter

This is where Taiwan’s regulatory framework becomes relevant, because the design is different.

Under the Regulations on the Publication of Regenerative Medicine Advertisements and Recruitment Advertisements, Taiwan requires pre-publication review for regenerative medicine advertising: ads must be approved before they run, and the content must be retained on file. Medical institutions apply for approval of their own advertising. Institutions, academic research organizations, or cell banks apply for approval of recruitment ads targeting tissue and cell donors.

Minister of Health and Welfare Shih Chung-liang addressed this requirement at an August 2026 forum. He offered an example: he had discovered, at dinner, a sake brand claiming to contain stem cells.

“I have no idea what the actual effect is. It seemed to make you less drunk, somehow. So stem cells seem to have become a very common phrase — something everyone has heard of — when in fact they are extraordinarily complex.”

He then explained the logic behind pre-publication review: “Unlike how advertising has worked in the past, this type of advertising requires prior application — to prevent people from being misled.”

Japan’s approach is post-publication enforcement. Article 6-5 of the Medical Care Act and the MHLW’s medical advertising guidelines prohibit exaggerated advertising, comparative superiority claims, inappropriate before-and-after images, and patient testimonials. Action is taken when a violation is found, not before.

Both approaches have legitimate rationales. Pre-publication review blocks misleading content before it reaches anyone, at the cost of administrative overhead and turnaround time. Post-publication enforcement is faster and lighter to administer, but by the time it acts, the harm has often already run its course.

For consumers, the practical difference is concrete: a regenerative medicine ad you see in Taiwan has, in theory, been reviewed by someone before it reached you. An ad you see on a foreign platform has not.

Where the Gap Is

This is where the gray area opens up.

A Japanese clinic writes a Traditional Chinese landing page, uses social media retargeting to place the ad in front of Taiwanese users, runs consultation sessions in Taipei, and delivers the actual medical services in Japan.

Taiwan’s pre-publication review system governs medical advertising published in Taiwan. Foreign institutions advertising on foreign platforms are, as a practical matter, beyond its reach.

Japan’s medical advertising regulations primarily address domestic medical institutions. Where foreign-language landing pages designed to funnel patients overseas fall on the enforcement priority list is a separate question.

Neither system was designed to handle this. Both work reasonably well within their own jurisdictions. Cross-border advertising passes through the middle.

The gap that remains is currently one that consumers have to bridge on their own.

That Document Is Searchable

Back to the photo of the filing document in the ad.

It was real. The clinic had submitted a treatment plan. The plan had been accepted. The document existed. No document was fabricated.

But the distance between “an accepted filing” and “the government has approved this therapy as effective” is roughly the distance between “I signed up for a marathon” and “I finished a marathon.” The document itself is genuine. The misleading element is how it is framed in the advertisement.

There is one practical upside: you can check for yourself. Japan’s database is public. The target conditions listed in each plan are written out in plain language. The comparison takes a few minutes.

Every ad of this kind depends on the same assumption: that you won’t look it up.

Once that assumption fails, the whole rhetorical structure has nothing to stand on.

My next piece will walk through the specific steps for verification: which fields to check and which phrases are warning signs. The one after that will address a more fundamental question: where mesenchymal stem cells actually go after intravenous infusion. That piece will explain why “one cell type treats forty conditions” is a claim that doesn’t hold up at the level of mechanism.

Key Points in This Article

  1. Treatment plans under Article 4 of Japan’s Act on the Safety of Regenerative Medicine are filed as 届出 — notifications — and carry no force of recognition or approval.
  2. Each treatment plan is tied to specific target conditions; the same technology applied to a different condition requires a separate filing.
  3. The 2026 edition of the MHLW’s case guidance added a dedicated chapter on out-of-pocket regenerative medicine, explicitly naming advertising that implies individual MHLW approval as a misleading advertising pattern.
  4. Taiwan’s Regulations on the Publication of Regenerative Medicine Advertisements and Recruitment Advertisements require pre-publication review; Japan relies on post-publication enforcement.
  5. Cross-border ads in foreign languages fall between both systems. For now, consumers have to bridge that gap themselves.

References

Japanese Regulations and Primary Government Documents

Japanese Academic Society

Public Database

Taiwan Regulations

  • Regenerative Medicine Act and Regenerative Medicine Preparations Act: promulgated June 19, 2024; effective January 1, 2026.
  • Regulations on the Publication of Regenerative Medicine Advertisements and Recruitment Advertisements: see the Laws and Regulations Database of the Republic of China (law.moj.gov.tw).
  • Minister Shih Chung-liang, “Advancing the Regenerative Medicine Act and International Alignment,” lecture delivered at the 2026 Life Sciences, Intellectual Property & Brand Finance International Summit, August 15, 2026. Remarks quoted here are drawn from the live transcript; a summary appears in this series’ coverage of the forum.

Series: Global Trends and Taiwan’s Position · The Design Logic of the Dual-Track System · Money, Speed, and the Asia-Pacific Rare Disease Innovation Treatment Center